Dulaglutide vs Decapeptide-12
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideSkin & Cosmetic
Decapeptide-12- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
- Half-Life
- ~5 days
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 5 ppm (0.0005%) concentration
- Frequency
- Once weekly
- Twice daily (AM and PM)
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Reduces hyperpigmentation and dark spots
- Evens skin tone and improves radiance
- Inhibits post-inflammatory hyperpigmentation
- Well-tolerated alternative to hydroquinone
- Effective for melasma and age spots
- Non-cytotoxic to melanocytes
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Generally very well-tolerated
- Rare mild irritation or sensitivity in some skin types
- Results may take several weeks to become visible
- Stacks With
- —
- —